Mannheim Pharma & Diagnostics
About Mannheim Pharma & Diagnostics
Mannheim Pharma & Diagnostics is a Healthcare company based in Mannheim (Germany), and was acquired by MediBeacon in June 2016. Provider of diagnostic solutions for gastrointestinal microbial assessment and measurement. Its chief executive, as recorded, is Steve Hanley. Its focus areas include Clinical Laboratories.
Company details
MAP Diagnostics is a company that specializes in diagnostic solutions for various applications. They offer the Gastrointestinal Microbial Assay Plus (GI-MAP), which is a clinical tool for measuring gastrointestinal microbiota DNA. They also provide MAP Growth, an assessment tool for measuring achievement and growth in K-12 math, reading, language usage, and science.
- Headquarters Mannheim, Germany
- Stage Acquired
- SectorsHealthcare
- Website mapdiagnostics.com
- Acquired by MediBeacon (Jun 2016)
- Investors
- Acquired byMediBeacon
(Jun 2016)
Investors in Mannheim Pharma & Diagnostics
Mannheim Pharma & Diagnostics has secured backing from 1 investor. Prominent investors backing the company include MediBeacon.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Non-invasive optical monitoring of kidney function is developed. | 2011 | medibeacon.com | St. Louis, United States |
Investor details for Mannheim Pharma Diagnostics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Mannheim Pharma & Diagnostics
1 people are tracked at Mannheim Pharma & Diagnostics (1 in leadership).
| Name | Role | Group |
|---|---|---|
Steve Hanley | CEO | Leadership |
Complete people profiles for Mannheim Pharma & Diagnostics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Mannheim Pharma & Diagnostics
Mannheim Pharma & Diagnostics is headquartered in Mannheim, Germany. It is registered at Mannheim, Baden-wurttemberg, Germany.
Steve Hanley is the CEO of Mannheim Pharma & Diagnostics, as recorded in our data.
MAP Diagnostics is a company that specializes in diagnostic solutions for various applications. They offer the Gastrointestinal Microbial Assay Plus (GI-MAP), which is a clinical tool for measuring gastrointestinal microbiota DNA. They also provide MAP Growth, an assessment tool for measuring achievement and growth in K-12 math, reading, language usage, and science.
Mannheim Pharma & Diagnostics has 1 investor. Key investors include MediBeacon.
Yes. Mannheim Pharma & Diagnostics was acquired by MediBeacon in June 2016.